Your activity: 2 p.v.
< Back

Oral budesonide formulations used in treatment of inflammatory bowel disease

Oral budesonide formulations used in treatment of inflammatory bowel disease
Brand names Type Description pH release Delivery Uses
  • Entocort EC (Canada, US)
  • Entocort CR, Entocir (EU, UK)
  • Ortikos (US)
NOTE: Generic equivalents may be available		 Controlled ileal release (CIR) formulation, pH- and time-dependent
  • Entocort EC, Entocort CR, Entocir:
    • 3 mg gelatin capsule filled with enteric-coated granules
  • Ortikos:
    • 6 mg gelatin capsule filled with pellets
    • 9 mg gelatin capsule filled with pellets
≥5.5 Terminal ileum and/or ascending colon Mild to moderately active Crohn of ileum and/or ascending colon
  • Budenofalk (EU, UK)
NOTE: Not available in US or Canada		 pH-dependent release
  • 3 mg gelatin capsule filled with enteric-coated granules
  • 9 mg sachet filled with enteric-coated granules
>6.4 Terminal ileum and/or ascending colon Mild to moderately active Crohn of ileum and/or ascending colon
  • Uceris (US)
  • Cortiment (Canada, EU, UK)
Multi-matrix (MMX) structure with gastric acid-resistant coating
  • 9 mg delayed- and extended-release tablet
≥7.0 Controlled delivery to ascending, transverse, and descending colon Mild to moderately active ulcerative colitis
Orally administered budesonide has high presystemic clearance and topical antiinflammatory activity.
EU: European Union; UK: United Kingdom; US: United States.
Adapted from: Iborra M, Alvarez-Sotomayor D, Nos P. Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014;7:39.
Additional data from:
  1. US FDA approved drug product information, available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (Accessed on September 13, 2017).
Graphic 116034 Version 2.0